Drug intelligence / Profile preview

ace inhibitors + angiotensin receptor blockers + beta blockers + calcium channel blockers

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

This is a combination of four classes of antihypertensive drugs used to manage high blood pressure and related cardiovascular conditions. The combination includes: - **ACE inhibitors** (angiotensin-converting enzyme inhibitors): These block the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced blood pressure. - **Angiotensin receptor blockers (ARBs)**: These block the action of angiotensin II at its receptor, also resulting in vasodilation and lower blood pressure. - **Beta blockers**: These reduce heart rate and cardiac output by blocking beta-adrenergic receptors, thereby lowering blood pressure. - **Calcium channel blockers**: These prevent calcium from entering cardiac and vascular smooth muscle cells, causing relaxation of vessels and reduction in heart workload. Each class has a distinct mechanism but all contribute synergistically to lowering blood pressure. Such multi-drug regimens are often used for patients with resistant hypertension or those who do not achieve target pressures with fewer agents. This combination is not typically available as a single fixed-dose product but may be prescribed as separate medications taken together[1][2][5].

02

Targets

AGTR1 (Angiotensin II Type-1 receptor)ACE (Angiotensin Converting Enzyme)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)ADRB1 (β1)

Beyond the preview

Go deeper on ace inhibitors + angiotensin receptor blockers + beta blockers + calcium channel blockers.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ace inhibitors + angiotensin receptor blockers + beta blockers + calcium channel blockers.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call